ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
Hemophilia A With Inhibitor
About this trial
This is an interventional treatment trial for Hemophilia A With Inhibitor
Eligibility Criteria
Inclusion Criteria Moderate or severe hemophilia A; Aged 14-66 years old; Inhibitor positive at 2 consecutive visits; Inhibitor titer > 10 BU at the screening visit. Exclusion Criteria: The patient has contraindications to drug ingredients or hamster protein allergy; Suffering from other immune diseases or Using immunosuppressant IS to treat another disease(s); Failed systemic ITI treatment in history; Poor patients compliance; The investigator believes that there are any other reasons that make the patient unsuitable to participate in this study.
Sites / Locations
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
SCT800 combined with Daratumumab
SCT800 alone
ITI using low-dose domestic rFVIII (SCT800) (50IU/kg TIW) and treated with Daratumumab 8mg/kg 4-8 times. Other immunosuppressants could be added after 3 months.
ITI using low-dose domestic rFVIII (SCT800) (50IU/kg TIW) alone. Other immunosuppressants could be added after 3 months.